Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events in Adults With Obesity and Autoimmune Disease: A Target Trial Emulation - PubMed
5 hours ago
- #GLP-1 agonists
- #cardiovascular risk
- #autoimmune obesity
- This retrospective cohort study used electronic health records (2014-2024) to assess GLP-1RA use in adults with obesity and autoimmune disease (AID), with matched 13,204 users and nonusers.
- GLP-1RA use was linked to significantly lower risks of stroke/transient ischemic attack, pulmonary embolism, venous thromboembolism, emergency department visits, and all-cause mortality.
- The findings suggest cardiovascular and survival benefits of GLP-1RAs in this high-risk group, supporting their potential role in reducing thromboembolic events and healthcare utilization.